In a filing, BridgeBio Pharma Inc revealed its Chief Executive Officer Kumar Neil unloaded Company’s shares for reported $2.98 million on Dec 04 ’25. In the deal valued at $74.40 per share,40,000 shares were sold. As a result of this transaction, Kumar Neil now holds 775,686 shares worth roughly $57.59 million.
Then, Kumar Neil sold 40,000 shares, generating $2,932,563 in total proceeds. Upon selling the shares at $73.31, the Chief Executive Officer now owns 755,686 shares.
Before that, Kumar Neil sold 26,156 shares. BridgeBio Pharma Inc shares valued at $1,722,224 were divested by the Chief Executive Officer at a price of $65.84 per share. As a result of the transaction, Kumar Neil now holds 228,776 shares, worth roughly $16.98 million.
A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. Jefferies began covering BBIO with “Buy” recommendation on July 14, 2025. Oppenheimer revised its rating on July 09, 2025. It rated BBIO as “an Outperform” which previously was an “a Perform”.
Price Performance Review of BBIO
On Monday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock jump 0.81% to $74.24. Over the last five days, the stock has gained 3.43%. BridgeBio Pharma Inc shares have risen nearly 173.95% since the year began. Nevertheless, the stocks have risen 170.55% over the past one year. While a 52-week high of $75.04 was reached on 12/08/25, a 52-week low of $25.34 was recorded on 01/02/25.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 73.59, which if violated will result in even more drops to 72.95. On the upside, there is a resistance level at 74.99. A further resistance level may holdings at 75.75.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-11-14, growing by 3.34 million shares to a total of 20.69 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 17.35 million shares. There was a rise of 16.13%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 17, 2025 when Wolfe Research began covering the stock and recommended ‘”an Outperform”‘ rating along with a $49 price target.
